CareyHwangMDPhD

Infectious Disease • Skillman, NJ

HIV/AIDS Medicine

Senior Vice President, Clinical Research, Head of Chronic Infection - Vir Biotechnology

Join to view full profile

Dr. Hwang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hwang's full profile

Already have an account?

Office
241 Sunset Rd
Skillman, NJ 08558
Phone+1 415-992-6293

Education & Training

Vanderbilt University Medical CenterFellowship, Infectious Disease, 2005 - 2009
Vanderbilt University Medical CenterResidency, Internal Medicine, 2003 - 2005
West Virginia University School of MedicineClass of 2003

Certifications & Licensure

TN State Medical License 2004 - 2019

Clinical Trials

HIV Resistance and Treatment Strategies Start of enrollment: 2007 Jan 01
Completed

Publications & Presentations

PubMed

112 citations
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immun...
Chloe Orkin, Kathleen Squires, Jean-Michel Molina, Paul E. Sax, Wing-Wai Wong
Clinical Infectious Diseases. 2019-02-01
18 citations
In Vitro Cross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations
Zhufang Li, Brian Terry, William Olds, Tricia Protack, Carol Deminie
Antimicrobial Agents and Chemotherapy. 2013-11-01
38 citations
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infecti...
Chloe Orkin, Kathleen Squires, Jean-Michel Molina, Paul E. Sax, Otto Sussmann
Clinical Infectious Diseases. 2020-12-18

Journal Articles

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Adults with Human Immun...
George J Hanna, Peter Sklar, Kathleen E Squires, Paul E Sax, Carey Hwang, Clinical Infectious Diseases

Press Mentions

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus InfectionSeptember 22nd, 2022
Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver ConferenceJune 27th, 2022
Vir Biotechnology Announces New Clinical Data from Its Broad Hepatitis B ProgramJune 27th, 2022
Join now to see all